RT Journal Article
SR Electronic
T1 Inflammation-based Prognostic Score for Hepatocellular Carcinoma Patients on Sorafenib Treatment
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 619
OP 623
VO 32
IS 2
A1 MANABU MORIMOTO
A1 KAZUSHI NUMATA
A1 SATOSHI MORIYA
A1 MASAAKI KONDO
A1 AKITO NOZAKI
A1 YU MORIOKA
A1 SHIN MAEDA
A1 KATSUAKI TANAKA
YR 2012
UL http://ar.iiarjournals.org/content/32/2/619.abstract
AB Background: No reliable prognostic predictor is known for patients undergoing sorafenib treatment for advanced hepatocellular carcinoma (HCC). Patients and Methods: In 81 patients receiving sorafenib treatment for advanced HCC, we evaluated the prognostic significance of an inflammation-based prognostic score, the Glasgow prognostic score [evidenced by an elevated C-reactive protein level (>1.0 mg/dl) and hypoalbuminemia (<3.5 g/dl)] and compared it with Child-Pugh grade, Barcelona Clinic Liver Cancer staging system, Japan Integrated Staging (JIS) score, and the performance status by Cox-proportional analysis. Results: Median overall survival after sorafenib administration was 11.3 months. On multivariate analysis, Glasgow prognostic score (0 vs. 1 and 2; p<0.001), JIS score (1 and 2 vs. 3 and 4; p=0.001), and performance status (0 vs. 1; p=0.001) were found to be independently associated with survival. Conclusion: The Glasgow prognostic score has significant prognostic value in patients undergoing sorafenib treatment for advanced HCC.